Work

A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer

Year: 2019

Type: article

Abstract: Immune checkpoint agents have not yet been approved for use in advanced prostate cancer. This commentary summarizes the challenges related to this issue, in light of a recently reported case of a patient with DNA mismatch‐repair deficient castration‐resistant prostate cancer who responded to single‐agent pembrolizumab treatment.

Source: The Oncologist

DOI: 10.1634/theoncologist.2018-0819

Author: Emmanuel S. Antonarakis

Institutions: Johns Hopkins University, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: U.S. Department of Defense, National Institutes of Health, National Cancer Institute, DOD Prostate Cancer Research Program